Reviewing DXC Technology (NYSE:DXC) and Portage Biotech (NASDAQ:ALP)

DXC Technology (NYSE:DXC – Get Free Report) and Portage Biotech (NASDAQ:ALP – Get Free Report) are both small-cap technology companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Risk and Volatility

DXC Technology has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Portage Biotech has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.

Institutional and Insider Ownership

96.2% of DXC Technology shares are held by institutional investors. Comparatively, 13.4% of Portage Biotech shares are held by institutional investors. 1.1% of DXC Technology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares DXC Technology and Portage Biotech’s net margins, return on equity and return on assets.

Valuation & Earnings

This table compares DXC Technology and Portage Biotech”s revenue, earnings per share and valuation.

DXC Technology has higher revenue and earnings than Portage Biotech. Portage Biotech is trading at a lower price-to-earnings ratio than DXC Technology, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for DXC Technology and Portage Biotech, as provided by MarketBeat.

DXC Technology currently has a consensus target price of $12.21, suggesting a potential upside of 9.37%. Portage Biotech has a consensus target price of $0.25, suggesting a potential downside of 94.49%. Given DXC Technology’s stronger consensus rating and higher probable upside, equities analysts clearly believe DXC Technology is more favorable than Portage Biotech.

Summary

DXC Technology beats Portage Biotech on 12 of the 13 factors compared between the two stocks.

About DXC Technology

(Get Free Report)

DXC Technology Company, together with its subsidiaries, provides information technology services and solutions in the United States, the United Kingdom, rest of Europe, Australia, and internationally. It operates in two segments, Global Business Services (GBS) and Global Infrastructure Services (GIS). The GBS segment offers a portfolio of analytics services and extensive partner ecosystem that help its customers to gain insights, automate operations, and accelerate their transformation journeys; and software engineering, consulting, and data analytics solutions, which enable businesses to run and manage their mission-critical functions, transform their operations, and develop new ways of doing business. This segment also simplifies, modernize, and accelerate mission-critical applications that support business agility and growth through applications services; provides proprietary modular insurance software and platforms; and operates a wide spectrum of insurance business process services, as well as helps to operate and improve bank cards, payment and lending process and operations, and customer experiences. The GIS segment offers security services, such as IT security, operations and culture for migrating to the cloud, protecting data with a zero-trust strategy, and manage a security operation center; and cloud infrastructure and IT outsourcing services. This segment also delivers a consumer-like experience, centralize IT management, and support services, as well as improves the total cost of ownership; and orchestrates hybrid cloud and multicloud environments. The company markets and sells its products through direct sales force to commercial businesses and public sector enterprises. DXC Technology Company was founded in 1959 and is headquartered in Ashburn, Virginia.

About Portage Biotech

(Get Free Report)

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company’s product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.